Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease
INTRODUCTION: Accumulating evidence supports the evaluation of glucagon-like peptide-1 (GLP-1) receptor (R) agonists for the treatment of the underlying pathology causing Parkinson's Disease (PD). Not only are these effects evident in models of PD and other neurodegenerative disorders but recently in a randomized, double-blind, placebo-controlled clinical trial, a GLP-1R agonist has provided improved cognition motor functions in humans with moderate PD.
AREAS COVERED: In this mini-review, we describe the development of GLP-1R agonists and their potential therapeutic value in treating PD. Many GLP-1R agonists are FDA approved for the treatment of metabolic disorders, and hence can be rapidly repositioned for PD. Furthermore, we present preclinical data offering insights into the use of monomeric dual- and tri-agonist incretin-based mimetics for neurodegenerative disorders. These drugs combine active regions of GLP-1 with those of glucose-dependent insulinotropic peptide (GIP) and/or glucagon (Gcg).
EXPERT OPINION: GLP-1Ragonists offer a complementary and enhanced therapeutic value to other drugs used to treat PD. Moreover, the use of the dual- or tri-agonist GLP-1-based mimetics may provide combinatory effects that are even more powerful than GLP-1R agonism alone. We advocate for further investigations into the repurposing of GLP-1R agonists and the development of classes of multi-agonists for PD treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Expert opinion on investigational drugs - 29(2020), 6 vom: 01. Juni, Seite 595-602 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Glotfelty, Elliot J [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.01.2021 Date Revised 06.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/13543784.2020.1764534 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309954924 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309954924 | ||
| 003 | DE-627 | ||
| 005 | 20231225135038.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13543784.2020.1764534 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1033.xml |
| 035 | |a (DE-627)NLM309954924 | ||
| 035 | |a (NLM)32412796 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Glotfelty, Elliot J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.01.2021 | ||
| 500 | |a Date Revised 06.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Accumulating evidence supports the evaluation of glucagon-like peptide-1 (GLP-1) receptor (R) agonists for the treatment of the underlying pathology causing Parkinson's Disease (PD). Not only are these effects evident in models of PD and other neurodegenerative disorders but recently in a randomized, double-blind, placebo-controlled clinical trial, a GLP-1R agonist has provided improved cognition motor functions in humans with moderate PD | ||
| 520 | |a AREAS COVERED: In this mini-review, we describe the development of GLP-1R agonists and their potential therapeutic value in treating PD. Many GLP-1R agonists are FDA approved for the treatment of metabolic disorders, and hence can be rapidly repositioned for PD. Furthermore, we present preclinical data offering insights into the use of monomeric dual- and tri-agonist incretin-based mimetics for neurodegenerative disorders. These drugs combine active regions of GLP-1 with those of glucose-dependent insulinotropic peptide (GIP) and/or glucagon (Gcg) | ||
| 520 | |a EXPERT OPINION: GLP-1Ragonists offer a complementary and enhanced therapeutic value to other drugs used to treat PD. Moreover, the use of the dual- or tri-agonist GLP-1-based mimetics may provide combinatory effects that are even more powerful than GLP-1R agonism alone. We advocate for further investigations into the repurposing of GLP-1R agonists and the development of classes of multi-agonists for PD treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Glucagon-like peptide-1 (GLP-1) | |
| 650 | 4 | |a Parkinson’s disease | |
| 650 | 4 | |a brain trauma | |
| 650 | 4 | |a glucagon (Gcg) | |
| 650 | 4 | |a glucose-dependent insulinotropic peptide (GIP) | |
| 650 | 4 | |a incretin mimetics | |
| 650 | 4 | |a microglia | |
| 650 | 4 | |a neurodegeneration | |
| 650 | 7 | |a Antiparkinson Agents |2 NLM | |
| 650 | 7 | |a Glucagon-Like Peptide-1 Receptor |2 NLM | |
| 700 | 1 | |a Olson, Lars |e verfasserin |4 aut | |
| 700 | 1 | |a Karlsson, Tobias E |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yazhou |e verfasserin |4 aut | |
| 700 | 1 | |a Greig, Nigel H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on investigational drugs |d 1995 |g 29(2020), 6 vom: 01. Juni, Seite 595-602 |w (DE-627)NLM093775326 |x 1744-7658 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2020 |g number:6 |g day:01 |g month:06 |g pages:595-602 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/13543784.2020.1764534 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2020 |e 6 |b 01 |c 06 |h 595-602 | ||